Latest news with #RegulationD
Yahoo
3 days ago
- Business
- Yahoo
Regulation D and savings account withdrawal limits – here's what changed
Regulation D previously limited withdrawals from savings and money market accounts to six per statement cycle. The Federal Reserve suspended this limit in April 2020 during the coronavirus pandemic to provide greater financial flexibility. Many banks still maintain withdrawal restrictions even though they're no longer federally required to do so. Understanding your bank's current policies helps you avoid unexpected fees and choose the right account for your needs. While banks historically limited the number of transactions customers could make each month in savings and money market accounts, a pandemic-era rule change means you may now have easier access to your funds. Regulation D, or Reg. D, is a Federal Reserve Board rule that previously limited withdrawals and transfers to six each statement cycle. The Fed revised the rule in 2020, but many banks have maintained the six-transaction limit while others have increased the number of allowable withdrawals and transfers. Regulation D imposed reserve requirements on banks' deposits and other liabilities to help implement monetary policy, according to the Federal Reserve. In April 2020, reserve requirements at banks were reduced to zero percent, where they've remained for more than five years. More importantly for consumers, Reg. D previously restricted the frequency of certain types of withdrawals and transfers you could make from a savings deposit account during a statement cycle. Banks no longer have to limit the number of certain withdrawals from savings deposit accounts to six, but most still restrict withdrawals on these accounts. The regulation distinguished between different types of accounts based on their intended purpose. Checking accounts are designated as transaction accounts under Reg. D, meaning they're designed for conducting day-to-day business like bill paying and making purchases. Savings and money market accounts are classified as nontransaction accounts, intended primarily for saving money rather than frequent transactions. Bankrate insight: The regulatory rationale Regulation D was originally designed to help the Federal Reserve manage monetary policy by controlling how much money banks needed to keep in reserve. The withdrawal limits helped maintain the distinction between savings accounts meant for saving and checking accounts meant for spending. In April 2020, as Americans began navigating the economic fallout from the coronavirus pandemic, the Fed deleted the six-transaction limit from the definition of savings deposit accounts via an interim final rule. This change was made to provide consumers with greater financial flexibility during uncertain times. Some banks immediately embraced the rule change by eliminating withdrawal limits entirely. American Express National Bank, for example, previously allowed nine withdrawals per statement cycle but now places no withdrawal limits on its savings account. Understanding which transactions count toward withdrawal limits helps you manage your accounts more effectively and avoid unexpected fees. Electronic transfers such as online bill pay, automatic transfers between accounts and transfers via mobile banking apps. Outgoing wire transfers from your savings account to other banks or individuals. Debit card purchases on money market accounts (savings accounts rarely offer debit cards). Automated payments set up through your bank's bill pay service or third-party services like Zelle. Overdraft protection transfers from your savings account to cover checking account overdrafts. ATM withdrawals and in-person transactions with bank tellers are generally exempt from Reg. D restrictions, even at banks that maintain withdrawal limits. This means you can still access your money when needed, though you may need to visit an ATM or branch. Even banks that maintain withdrawal limits typically provide several ways to access your money without penalties. ATM and teller transactions remain unlimited at most institutions. You can withdraw cash at ATMs or visit a branch to speak with a teller without affecting your transaction count. and incoming transfers don't count toward withdrawal limits since they add money to your account rather than removing it. Interest payments and other bank-initiated transactions are excluded from customer transaction limits. Account-to-account transfers within the same bank may be treated differently depending on the institution's policies, so check with your specific bank. Money tip: If your bank maintains withdrawal limits, plan larger, less frequent transfers rather than multiple small ones. For example, transfer your monthly expenses in one transaction rather than paying bills individually from your savings account. Understanding your bank's current withdrawal policies is crucial when shopping for savings accounts or managing your existing accounts effectively. Account selection considerations: A savings account might not be the right choice if you need frequent access to your funds and your bank maintains strict withdrawal limits. However, if the bank allows many or unlimited withdrawals, it could work well for your needs. Fee avoidance: Many banks charge excess transaction fees of $5-$15 for each withdrawal beyond their limit. These fees can quickly add up and erode your interest earnings, especially on smaller balances. Account conversion risks: Some banks automatically convert savings accounts to checking accounts if you consistently exceed transaction limits. This conversion often comes with different fee structures and lower interest rates. Financial planning benefits: Knowing your limits helps you structure your finances more effectively. You might choose to keep more money in high-yield checking accounts for frequent transactions while using savings accounts for longer-term goals. When comparing accounts, look for institutions that either eliminate withdrawal limits entirely or make them generous enough for your needs. Online banks often offer more flexibility than traditional banks in this area. Is Regulation D still suspended? Regulation D withdrawal limits are officially suspended at the federal level, meaning banks are not required to impose the six-transaction limit. However, this suspension was implemented as an interim rule, not a permanent change. Many banks choose to maintain their own withdrawal restrictions as internal policies, so the practical impact varies by institution. What are the requirements of Regulation D? Currently, Regulation D requires banks to maintain reserve requirements (though these are set at zero percent) and classify accounts as either transaction or nontransaction accounts. The regulation no longer mandates withdrawal limits on savings accounts, but banks can choose to impose their own restrictions as part of their account terms and conditions. What happens if I exceed transaction limits? If your bank maintains withdrawal limits and you exceed them, you'll typically face excess transaction fees ranging from $5 to $15 per additional transaction. Some banks may also send warnings or temporarily restrict electronic access to your account. Repeated violations could result in your account being converted to a checking account or closed entirely. What can I do if I need cash after reaching the limit? If you've reached your monthly transaction limit, you can still access your money through ATM withdrawals or by visiting a bank branch to speak with a teller. These transactions typically don't count toward your electronic transaction limit. You can also wait until your next statement cycle begins to resume electronic transfers. How can I maximize savings under Regulation D? To optimize your savings strategy, consider keeping funds you need regular access to in a high-yield checking account or money market account with generous transaction allowances. Use traditional savings accounts for longer-term goals where you won't need frequent access. This approach helps you earn competitive rates while avoiding transaction limit issues. How can I avoid fees related to Regulation D? To avoid withdrawal limit fees, track your monthly transactions and plan larger, less frequent transfers when possible. Set up automatic transfers at the beginning of each month rather than making multiple smaller withdrawals. Consider using ATMs or visiting branches when you need cash, and choose banks that offer generous withdrawal allowances or eliminate limits entirely.
Yahoo
4 days ago
- Business
- Yahoo
Cove Capital Investments Announces It Has Fully Subscribed Its San Antonio Multifamily 74 Delaware Statutory Trust Offering After Raising Nearly $19 Million from Accredited Investors
The historic "Peanut Factory Lofts" successfully sells out after securing $18,679,418 from accredited investors. LOS ANGELES, May 30, 2025 /PRNewswire/ -- Cove Capital Investments, LLC, a DST sponsor company that specializes in providing accredited investors access to debt-free investment options for their 1031 exchange and direct cash investments, announced its San Antonio Multifamily 74 Delaware Statutory Trust Offering, a Regulation D, Rule 506(c) Delaware Statutory Trust offering, is fully subscribed. The total amount of equity raised for the offering was $18,679,418. "The successful sellout of the DST reflects strong investor confidence in Cove Capital's abilities and our commitment to acquiring high quality assets in key markets across the country. The Peanut Factory Lofts was a great example of this strategy in action, and how our debt-free investment thesis continues to appeal to our growing group of investors, broker dealers, and RIAs," said Dwight Kay, Managing Member and Co-Founder of Cove Capital Investments. According to Kay, the San Antonio Multifamily 74 DST had some very unique characteristics that made it an attractive acquisition. "For example, the property has a appealing mix of dwelling units including one-, two-, and three-bedroom floorplans, townhomes, and a penthouse. This selection perfectly aligns with the historic downtown San Antonio market where the building is located," said Kay. Additionally, the 96,184-square-foot Peanut Factory Lofts, built in 2014, features 102 units and 127 parking spaces. Residents enjoy premium amenities such as private garages, a coffee bar, a landscaped courtyard, door-to-door trash pickup, a dog park, a fitness center, and a resort-style pool with a cabana. According to Chay Lapin, Managing Member and Co-Founder of Cove Capital, the San Antonio Multifamily 74 DST offering had several architectural aspects that attracted investors. For example, the asset was originally constructed as a peanut processing plant and then converted into 'The Peanut Factory Lofts' - a Class-A apartment community in 2014. The unique history of the building, combined with its proximity to San Antonio's trendy Southtown, Historic King William District, Blue Star Arts Complex, and Historic Market Square, gives the building a distinct contemporary-urban aesthetic. The building also incorporated some of the original silos, now transformed into modern apartments, along with a three-bedroom penthouse with a balcony and rooftop access. "On top of these elements, investors also appreciated our all-cash position, which ensured closing certainty—critical for securing this unique asset," said Chay Lapin, Managing Member and Co-Founder of Cove Capital. "We are excited to begin our list of property level improvements on behalf of our investors in an effort to potentially increase Net Operating Income (NOI) and property value." About Cove Capital Investments Cove Capital Investments is a Delaware Statutory Trust sponsor company that operates a portfolio of over 2.5 million square feet of real estate in 33 states nationwide. Over 2,000 investors have trusted Cove Capital with their 1031 exchange and investment dollars, many of them being repeat investors in multiple DST offerings over the years. Our offerings are attractive to those investors seeking to lower risk potential as the majority of Cove Capital's DST offerings are debt free (no mortgage - no lender foreclosure risk). To sign up for a list of the current Cove Capital offerings available for 1031 exchange and direct investments please visit For further information, please visit or contact Cove Capital at (877) 899-1315 and via email at info@ *Past performance is no guarantee of future results. *Diversification does not guarantee profits or protect against losses. *This material does not constitute an offer to sell nor a solicitation of an offer to buy any security. Such offers can be made only by the confidential Private Placement Memorandum (the "Memorandum"). Please read the entire Memorandum paying special attention to the risk section prior to investing. This material contains information that has been obtained from sources believed to be reliable. However, Cove Capital Investments, LLC does not guarantee the accuracy and validity of the information herein. Investors should perform their own investigations before considering any investment. IRC Section 1031, IRC Section 1033 and IRC Section 721 are complex tax codes therefore you should consult your tax or legal professional for details regarding your situation. This material is not intended as tax or legal advice. There are material risks associated with investing in real estate, Delaware Statutory Trust (DST) properties and real estate securities including illiquidity, tenant vacancies, general market conditions and competition, lack of operating history, interest rate risks, the risk of new supply coming to market and softening rental rates, general risks of owning/operating commercial and multifamily properties, short term leases associated with multi-family properties, financing risks, potential adverse tax consequences, general economic risks, development risks and long hold periods. There is a risk of loss of the entire investment principal. Past performance is not a guarantee of future results. Potential cash flow, potential returns and potential appreciation are not guaranteed. For an investor to qualify for any type of investment, there are both financial requirements and suitability requirements that must match specific objectives, goals and risk tolerances. Securities offered through FNEX Capital, member FINRA, SIPC. View original content to download multimedia: SOURCE Cove Capital Investments Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Cove Capital Investments Announces It Has Fully Subscribed Its San Antonio Multifamily 74 Delaware Statutory Trust Offering After Raising Nearly $19 Million from Accredited Investors
The historic "Peanut Factory Lofts" successfully sells out after securing $18,679,418 from accredited investors. LOS ANGELES, May 30, 2025 /PRNewswire/ -- Cove Capital Investments, LLC, a DST sponsor company that specializes in providing accredited investors access to debt-free investment options for their 1031 exchange and direct cash investments, announced its San Antonio Multifamily 74 Delaware Statutory Trust Offering, a Regulation D, Rule 506(c) Delaware Statutory Trust offering, is fully subscribed. The total amount of equity raised for the offering was $18,679,418. "The successful sellout of the DST reflects strong investor confidence in Cove Capital's abilities and our commitment to acquiring high quality assets in key markets across the country. The Peanut Factory Lofts was a great example of this strategy in action, and how our debt-free investment thesis continues to appeal to our growing group of investors, broker dealers, and RIAs," said Dwight Kay, Managing Member and Co-Founder of Cove Capital Investments. According to Kay, the San Antonio Multifamily 74 DST had some very unique characteristics that made it an attractive acquisition. "For example, the property has a appealing mix of dwelling units including one-, two-, and three-bedroom floorplans, townhomes, and a penthouse. This selection perfectly aligns with the historic downtown San Antonio market where the building is located," said Kay. Additionally, the 96,184-square-foot Peanut Factory Lofts, built in 2014, features 102 units and 127 parking spaces. Residents enjoy premium amenities such as private garages, a coffee bar, a landscaped courtyard, door-to-door trash pickup, a dog park, a fitness center, and a resort-style pool with a cabana. According to Chay Lapin, Managing Member and Co-Founder of Cove Capital, the San Antonio Multifamily 74 DST offering had several architectural aspects that attracted investors. For example, the asset was originally constructed as a peanut processing plant and then converted into 'The Peanut Factory Lofts' - a Class-A apartment community in 2014. The unique history of the building, combined with its proximity to San Antonio's trendy Southtown, Historic King William District, Blue Star Arts Complex, and Historic Market Square, gives the building a distinct contemporary-urban aesthetic. The building also incorporated some of the original silos, now transformed into modern apartments, along with a three-bedroom penthouse with a balcony and rooftop access. "On top of these elements, investors also appreciated our all-cash position, which ensured closing certainty—critical for securing this unique asset," said Chay Lapin, Managing Member and Co-Founder of Cove Capital. "We are excited to begin our list of property level improvements on behalf of our investors in an effort to potentially increase Net Operating Income (NOI) and property value." About Cove Capital Investments Cove Capital Investments is a Delaware Statutory Trust sponsor company that operates a portfolio of over 2.5 million square feet of real estate in 33 states nationwide. Over 2,000 investors have trusted Cove Capital with their 1031 exchange and investment dollars, many of them being repeat investors in multiple DST offerings over the years. Our offerings are attractive to those investors seeking to lower risk potential as the majority of Cove Capital's DST offerings are debt free (no mortgage - no lender foreclosure risk). To sign up for a list of the current Cove Capital offerings available for 1031 exchange and direct investments please visit For further information, please visit or contact Cove Capital at (877) 899-1315 and via email at info@ *Past performance is no guarantee of future results. *Diversification does not guarantee profits or protect against losses. *This material does not constitute an offer to sell nor a solicitation of an offer to buy any security. Such offers can be made only by the confidential Private Placement Memorandum (the "Memorandum"). Please read the entire Memorandum paying special attention to the risk section prior to investing. This material contains information that has been obtained from sources believed to be reliable. However, Cove Capital Investments, LLC does not guarantee the accuracy and validity of the information herein. Investors should perform their own investigations before considering any investment. IRC Section 1031, IRC Section 1033 and IRC Section 721 are complex tax codes therefore you should consult your tax or legal professional for details regarding your situation. This material is not intended as tax or legal advice. There are material risks associated with investing in real estate, Delaware Statutory Trust (DST) properties and real estate securities including illiquidity, tenant vacancies, general market conditions and competition, lack of operating history, interest rate risks, the risk of new supply coming to market and softening rental rates, general risks of owning/operating commercial and multifamily properties, short term leases associated with multi-family properties, financing risks, potential adverse tax consequences, general economic risks, development risks and long hold periods. There is a risk of loss of the entire investment principal. Past performance is not a guarantee of future results. Potential cash flow, potential returns and potential appreciation are not guaranteed. For an investor to qualify for any type of investment, there are both financial requirements and suitability requirements that must match specific objectives, goals and risk tolerances. Securities offered through FNEX Capital, member FINRA, SIPC. View original content to download multimedia: SOURCE Cove Capital Investments Sign in to access your portfolio
Business Upturn
5 days ago
- Business
- Business Upturn
IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J., May 28, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today closed on the previously announced sale of an aggregate of 7,222,223 shares of its common stock (or pre-funded warrants in lieu therof) and short-term warrants to purchase up to an aggregate of 14,444,446 shares of common stock at a purchase price of $0.45 per share (or pre-funded warrant in lieu thereof) and accompanying short-term warrants in a private placement priced at-the-market under Nasdaq rules. The warrants are exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the warrants at an exercise price of $0.45 per share and will expire three years from the date of stockholder approval. H.C. Wainwright & Co. acted as the exclusive lead placement agent for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as co-placement agent. The aggregate gross proceeds to the Company from the private placement was approximately $3.25 million, before deducting placement agent fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the short-term warrants, if fully-exercised on a cash basis, will be approximately $6.5 million. No assurance can be given that any of such short-term warrants will be exercised. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. The shares of common stock, pre-funded warrants and short-term warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Act') and Regulation D promulgated thereunder and, along with the shares of common stock underlying the pre-funded warrants and short-term warrants, have not been registered under the Act or applicable state securities laws. Accordingly, the shares of common stock, the pre-funded warrants, the short-term warrants and the shares of common stock underlying the pre-funded warrants and short-term warrants may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ('SEC') or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock and the shares issuable upon exercise of the pre-funded warrants and short-term warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About IMUNON IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit Forward-Looking Statements IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding expectations regarding the use of proceeds from the offering, the receipt of stockholder approval, the exercise of the short-term warrants prior to their expiration, and the Company's plans and expectations with respect to its development programs, are forward-looking statements. We generally identify forward-looking statements by using words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'estimate,' 'intend' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, risks and uncertainties related to market conditions and uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON's filings with the SEC. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise. Contacts: Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
5 days ago
- Business
- Yahoo
IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today closed on the previously announced sale of an aggregate of 7,222,223 shares of its common stock (or pre-funded warrants in lieu therof) and short-term warrants to purchase up to an aggregate of 14,444,446 shares of common stock at a purchase price of $0.45 per share (or pre-funded warrant in lieu thereof) and accompanying short-term warrants in a private placement priced at-the-market under Nasdaq rules. The warrants are exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the warrants at an exercise price of $0.45 per share and will expire three years from the date of stockholder approval. H.C. Wainwright & Co. acted as the exclusive lead placement agent for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as co-placement agent. The aggregate gross proceeds to the Company from the private placement was approximately $3.25 million, before deducting placement agent fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the short-term warrants, if fully-exercised on a cash basis, will be approximately $6.5 million. No assurance can be given that any of such short-term warrants will be exercised. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. The shares of common stock, pre-funded warrants and short-term warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Act') and Regulation D promulgated thereunder and, along with the shares of common stock underlying the pre-funded warrants and short-term warrants, have not been registered under the Act or applicable state securities laws. Accordingly, the shares of common stock, the pre-funded warrants, the short-term warrants and the shares of common stock underlying the pre-funded warrants and short-term warrants may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ('SEC') or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock and the shares issuable upon exercise of the pre-funded warrants and short-term warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About IMUNON IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit Forward-Looking Statements IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding expectations regarding the use of proceeds from the offering, the receipt of stockholder approval, the exercise of the short-term warrants prior to their expiration, and the Company's plans and expectations with respect to its development programs, are forward-looking statements. We generally identify forward-looking statements by using words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'estimate,' 'intend' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, risks and uncertainties related to market conditions and uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON's filings with the SEC. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise. Contacts: Media Investors Jenna Urban Peter Vozzo CG life ICR Healthcare 212-253-8881 443-213-0505 jurban@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
